Close Menu
  • Home
  • Finance News
  • Personal Finance
  • Investing
  • Cards
    • Credit Cards
    • Debit
  • Insurance
  • Loans
  • Mortgage
  • More
    • Save Money
    • Banking
    • Taxes
    • Crime
What's Hot

Stocks making big moves midday: ORCL ASTS, RVMD

October 18, 2025

US seizes $15 billion in huge bust of cybercriminal group

October 18, 2025

Democrats seek ACA enhanced subsidy deal as retirees face premium hikes

October 18, 2025
Facebook X (Twitter) Instagram
Facebook X (Twitter) Instagram
Smart SpendingSmart Spending
Subscribe
  • Home
  • Finance News
  • Personal Finance
  • Investing
  • Cards
    • Credit Cards
    • Debit
  • Insurance
  • Loans
  • Mortgage
  • More
    • Save Money
    • Banking
    • Taxes
    • Crime
Smart SpendingSmart Spending
Home»Finance News»Stocks making the biggest moves midday : ULCC, KHC, PEP, BIIB
Finance News

Stocks making the biggest moves midday : ULCC, KHC, PEP, BIIB

September 2, 2025No Comments3 Mins Read
Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
Stocks making the biggest moves midday : ULCC, KHC, PEP, BIIB
Share
Facebook Twitter LinkedIn Pinterest Email

Check out the companies making the biggest moves in midday trading: Frontier Group — Shares of the budget airline carrier shot up more than 13% in the wake of rival Spirit Airlines’ bankruptcy filing on Friday. Humana — Shares of the health insurer rose more than 2% after the company reaffirmed on Friday its fiscal 2025 earnings forecast. Humana expects to earn about $17 per share after adjustments. Following the announcement, Bank of America raised its price target, but reiterated its neutral stance on the stock United Therapeutics — The biotech soared 35% after saying its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution to treat idiopathic pulmonary fibrosis met its primary efficacy endpoint . Ionis Pharmaceuticals — The maker of RNA-targeted medicines jumped 32% when it said Phase 3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyceridemia showed ” a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% and a highly statistically significant reduction in acute pancreatitis events of 85% with favorable safety and tolerability.” PepsiCo — The snack and beverage giant rose more than 2% after activist investor Elliott Management took a $4 billion stake in the company, touting a “rare” and “historic” opportunity for a turnaround at the iconic soft drink and snack company. The investment by Elliott, founded by Paul Singer, was first reported by the Wall Street Journal . Elliott, now one of Pepsi’s five largest active investors, sent a presentation and letter to Pepsi’s board of directors Tuesday, detailing an agenda for restoring business momentum. Kraft Heinz — Shares tumbled nearly 7% after the food company confirmed earlier reports that it would split up into two publicly traded companies , which will be nameded at a later date. One unit, which currently goes by “Global Taste Elevation,” will include Kraft’s shelf-stable products such as Heinz and Kraft Mac & Cheese. The other one, “North American Grocery,” will include brands such as Oscar Mayer and Lunchables. Constellation Brands — The stock tumbled 7% after the brewer cut its full-year guidance. It now expects earnings to come in between $10.77 and $11.07 per share, down from its prior guidance of $12.07 and $12.37 per share. Air Lease — Shares rose more than 6% after the aircraft leasing company reached a merger deal with Apollo, Brookfield, SMBC Aviation Capital and Sumitomo. The deal, which is expected to close in the first half of next year, values the company at about $28.2 billion including debt. Cytokinetics — The late-stage biopharmaceutical company soared 40% after it said a clinical trial of its heart disease drug, aficamten, showed a meaningful improvement in patients with symptomatic obstructive hypertrophic cardiomyopathy, than the standard of care, metoprolol. Lam Research — The stock fell 4% following a downgrade at Morgan Stanley to underweight from equal weight. The bank said it doesn’t expect Lam Research to sustain growth into 2026. Biogen — The biopharma stock added almost 4% after Biogen and Eisai’s said the Food and Drug Administration approved an injectable version of their Alzheimer’s disease drug, Leqembi. Newmont — The gold miner gained 2% after the precious metal hit a record high of $3,508.50 earlier in Tuesday’s session. —CNBC’s Scott Schnipper, Michelle Fox, Fred Imbert and Alex Harring contributed reporting.

See also  How to save for college in a volatile market

Source link

Biggest BIIB KHC Making midday Moves PEP stocks ULCC
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
Previous ArticleProgressive lawmakers press banks on overdraft fees
Next Article Will a Fed Rate Cut Lead to Lower Mortgage Rates?

Related Posts

Stocks making big moves midday: ORCL ASTS, RVMD

October 18, 2025

Democrats seek ACA enhanced subsidy deal as retirees face premium hikes

October 18, 2025

Gold’s record run could be death knell for 60/40 stock bond portfolio

October 18, 2025
Add A Comment
Leave A Reply Cancel Reply

Top Posts

Chime’s IPO Poised To Pop, Even As It Faces Long-Term Challenges

June 11, 2025

How To Open a 401(k) Without an Employer in 2025

May 6, 2025

‘Something great with crypto:’ Trump affirms bitcoin reserve

December 16, 2024
Ads Banner

Subscribe to Updates

Subscribe to Get the Latest Financial Tips and Insights Delivered to Your Inbox!

Stay informed with our finance blog! Get expert insights, money management tips, investment strategies, and the latest financial news to help you make smart financial decisions.

We're social. Connect with us:

Facebook X (Twitter) Instagram YouTube
Top Insights

Stocks making big moves midday: ORCL ASTS, RVMD

October 18, 2025

US seizes $15 billion in huge bust of cybercriminal group

October 18, 2025

Democrats seek ACA enhanced subsidy deal as retirees face premium hikes

October 18, 2025
Get Informed

Subscribe to Updates

Subscribe to Get the Latest Financial Tips and Insights Delivered to Your Inbox!

© 2025 Smartspending.ai - All rights reserved.
  • Contact
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.